Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients
Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following infection is crucial to inform vaccination strategies for this highly vulnerable population. This cross-sectional study documents the anti-SARS-CoV-2 humoral response and serum neutralizing activity in...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764505/ https://www.ncbi.nlm.nih.gov/pubmed/35042847 http://dx.doi.org/10.1038/s41408-022-00608-6 |
_version_ | 1784634182156156928 |
---|---|
author | Borgogna, Cinzia Bruna, Riccardo Griffante, Gloria Martuscelli, Licia De Andrea, Marco Ferrante, Daniela Patriarca, Andrea Mahmoud, Abdurraouf Mokhtar Gaidano, Valentina Marchetti, Monia Rapezzi, Davide Lai, Michele Pistello, Mauro Ladetto, Marco Massaia, Massimo Gaidano, Gianluca Gariglio, Marisa |
author_facet | Borgogna, Cinzia Bruna, Riccardo Griffante, Gloria Martuscelli, Licia De Andrea, Marco Ferrante, Daniela Patriarca, Andrea Mahmoud, Abdurraouf Mokhtar Gaidano, Valentina Marchetti, Monia Rapezzi, Davide Lai, Michele Pistello, Mauro Ladetto, Marco Massaia, Massimo Gaidano, Gianluca Gariglio, Marisa |
author_sort | Borgogna, Cinzia |
collection | PubMed |
description | Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following infection is crucial to inform vaccination strategies for this highly vulnerable population. This cross-sectional study documents the anti-SARS-CoV-2 humoral response and serum neutralizing activity in 189 HM patients recovering from a PCR-confirmed infection. The overall seroconversion rate was 85.7%, with the lowest values in patients with lymphoid malignancies or undergoing chemotherapy. Therapy-naive patients in the “watch and wait” status were more likely to seroconvert and display increased anti-s IgG titers. Enhanced serum neutralizing activity was observed in the following SARS-CoV-2-infected HM patient groups: (i) males; (ii) severe COVID-19; and (iii) “watch and wait” or “complete/partial response”. The geometric mean (GeoMean) ID50 neutralization titers in patients analyzed before or after 6 months post-infection were 299.1 and 306.3, respectively, indicating that >50% of the patients in either group had a neutralization titer sufficient to provide 50% protection from symptomatic COVID-19. Altogether, our findings suggest that therapy-naive HM patients mount a far more robust immune response to SARS-CoV-2 infection vs. patients receiving anti-cancer treatment, raising the important question as to whether HM patients should be vaccinated before therapy and/or receive vaccine formats capable of better recapitulating the natural infection. |
format | Online Article Text |
id | pubmed-8764505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-87645052022-01-18 Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients Borgogna, Cinzia Bruna, Riccardo Griffante, Gloria Martuscelli, Licia De Andrea, Marco Ferrante, Daniela Patriarca, Andrea Mahmoud, Abdurraouf Mokhtar Gaidano, Valentina Marchetti, Monia Rapezzi, Davide Lai, Michele Pistello, Mauro Ladetto, Marco Massaia, Massimo Gaidano, Gianluca Gariglio, Marisa Blood Cancer J Article Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following infection is crucial to inform vaccination strategies for this highly vulnerable population. This cross-sectional study documents the anti-SARS-CoV-2 humoral response and serum neutralizing activity in 189 HM patients recovering from a PCR-confirmed infection. The overall seroconversion rate was 85.7%, with the lowest values in patients with lymphoid malignancies or undergoing chemotherapy. Therapy-naive patients in the “watch and wait” status were more likely to seroconvert and display increased anti-s IgG titers. Enhanced serum neutralizing activity was observed in the following SARS-CoV-2-infected HM patient groups: (i) males; (ii) severe COVID-19; and (iii) “watch and wait” or “complete/partial response”. The geometric mean (GeoMean) ID50 neutralization titers in patients analyzed before or after 6 months post-infection were 299.1 and 306.3, respectively, indicating that >50% of the patients in either group had a neutralization titer sufficient to provide 50% protection from symptomatic COVID-19. Altogether, our findings suggest that therapy-naive HM patients mount a far more robust immune response to SARS-CoV-2 infection vs. patients receiving anti-cancer treatment, raising the important question as to whether HM patients should be vaccinated before therapy and/or receive vaccine formats capable of better recapitulating the natural infection. Nature Publishing Group UK 2022-01-18 /pmc/articles/PMC8764505/ /pubmed/35042847 http://dx.doi.org/10.1038/s41408-022-00608-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Borgogna, Cinzia Bruna, Riccardo Griffante, Gloria Martuscelli, Licia De Andrea, Marco Ferrante, Daniela Patriarca, Andrea Mahmoud, Abdurraouf Mokhtar Gaidano, Valentina Marchetti, Monia Rapezzi, Davide Lai, Michele Pistello, Mauro Ladetto, Marco Massaia, Massimo Gaidano, Gianluca Gariglio, Marisa Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients |
title | Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients |
title_full | Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients |
title_fullStr | Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients |
title_full_unstemmed | Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients |
title_short | Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients |
title_sort | patterns of neutralizing humoral response to sars-cov-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764505/ https://www.ncbi.nlm.nih.gov/pubmed/35042847 http://dx.doi.org/10.1038/s41408-022-00608-6 |
work_keys_str_mv | AT borgognacinzia patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT brunariccardo patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT griffantegloria patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT martuscellilicia patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT deandreamarco patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT ferrantedaniela patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT patriarcaandrea patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT mahmoudabdurraoufmokhtar patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT gaidanovalentina patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT marchettimonia patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT rapezzidavide patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT laimichele patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT pistellomauro patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT ladettomarco patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT massaiamassimo patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT gaidanogianluca patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients AT garigliomarisa patternsofneutralizinghumoralresponsetosarscov2infectionamonghematologicmalignancypatientsrevealarobustimmuneresponseinanticancertherapynaivepatients |